title: Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients:  a randomized trial.
authors: Josep M
authors: JM
authors: Campistol
authors: Agustín
authors: A
authors: Carreño
authors: José M
authors: JM
authors: Morales
authors: Luis
authors: L
authors: Pallardó
authors: Antonio
authors: A
authors: Franco
authors: Dolores
authors: D
authors: Navarro
authors: Josep M
authors: JM
authors: Grinyó
authors: Jesús
authors: J
authors: Montenegro
authors: Ana I
authors: AI
authors: Sánchez Fructuoso
authors: Ramón
authors: R
authors: Romero
authors: Luis
authors: L
authors: Guirado
authors: Manuel
authors: M
authors: Arias
mesh_terms: D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D002908:Chronic Disease; D000068256:Darbepoetin alfa; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006397:Hematinics; D006454:Hemoglobins; C508420:continuous erythropoietin receptor activator; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D011092:Polyethylene Glycols